Dr Amitkumar Mehta: CAR T-Cell and Bispecific Therapy Are Co

Amitkumar Mehta, MD, MBA, University of Alabama at Birmingham, notes the long-term data and potential curative effects of chimeric antigen receptor (CAR) T-cell therapy, while expressing optimism about bispecific therapy with ongoing evolution and the chance of significant patient responses.

Related Keywords

Amitkumar Mehta , University Of Alabama At Birmingham , Cell Therapy , Cost Consideration , Patient Centered Oncology , Pcoc , Oncology , Cart Cell Therapy , Bispecifics , Lymphoma ,